ATC Group: J01GB Other aminoglycosides

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01GB in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01G Aminoglycoside antibacterials
4 J01GB Other aminoglycosides

Group J01GB contents

Code Title
J01GB01 Tobramycin
J01GB03 Gentamicin
J01GB04 Kanamycin
J01GB05 Neomycin
J01GB06 Amikacin
J01GB07 Netilmicin
J01GB08 Sisomicin
J01GB09 Dibekacin
J01GB10 Ribostamycin
J01GB11 Isepamicin
J01GB12 Arbekacin
J01GB13 Bekanamycin
J01GB14

Active ingredients in J01GB

Active Ingredient Description
Amikacin

Amikacin is an antibiotic used for a number of bacterial infections. Amikacin works by blocking the function of the bacteria’s 30S ribosomal subunit, making it unable to produce proteins.

Gentamicin

Gentamicin is usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drug appears to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits.

Kanamycin

Kanamycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth.

Neomycin

Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.

Netilmicin
Plazomicin

Plazomicin is an aminoglycoside antibacterial. It is used for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.

Sisomicin
Tobramycin

Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.

Related product monographs

Title Information Source Document Type  
AMIKIN INJECTION Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ARIKAYCE Inhalation suspension FDA, National Drug Code (US) MPI, US: SPL/PLR
GENTAMICIN Eye / Ear drops Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GENTAMICIN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIVEMYCIN Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SELEMYCIN Solution for injection/infusion Υπουργείο Υγείας (CY) MPI, EU: SmPC
TOBI Podhaler Inhalation powder, hard capsule European Medicines Agency (EU) MPI, EU: SmPC
TOBRAMYCIN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TYMBRINEB Nebuliser solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC